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A complex decision path with a careful evaluation of the risk–benefit ratio is mandatory
for drug treatment in advanced age. Enrollment biases in randomized clinical trials (RCTs)
cause an under-representation of older individuals. In high-risk frail older subjects, the lack
of RCTs makes clinical decision-making particularly difficult. Frail individuals are markedly
susceptible to adverse drug reactions, and frailty may result in reduced treatment efficacy.
Life expectancy should be included in clinical decision-making paths to better assess the
benefits and risks of different drug treatments in advanced age. We performed a scoping
review of principal hospital- and community-based prognostic indices in older age. Mor-
tality prognostic tools could help clinical decision-making in diagnostics and therapeutics,
tailoring appropriate intervention for older patients. The effectiveness of drug treatments
may be significantly different in older patients with different risk of mortality. Clinicians need
to consider the prognostic information obtained through well-validated, accurate, and cal-
ibrated predictive tools to identify those patients who may benefit from drug treatments
given with the aim of increasing survival.
Keywords: older age, frailty, clinical decision-making, multidimensional prognostic index, comprehensive geriatric
assessment
EVIDENCE-BASED MEDICINE IN OLDER AGE
Drug treatment in advanced age is achieved through a complex
decision path requiring a careful evaluation of the risk–benefit
ratio. Age-related changes in response to drugs can arise from
pharmacokinetic and pharmacodynamic differences. However,
age itself is not the only factor that could affect pharmacoki-
netic and pharmacodynamic responses to drugs in older people.
Although guidelines pertaining to the inclusion of older partici-
pants in randomized clinical trials (RCTs) have existed for more
than two decades (1), different studies and systematic reviews
suggested ongoing enrollment biases with under-representation
of older individuals especially in clinical trials of cardiovascular
diseases (2–4) and cancer (5, 6). In fact, older adults remain under-
represented in clinical trials of patients hospitalized with an acute
coronary syndrome (2) or in ongoing RCTs regarding heart failure
(3), while a very recent systematic review found that no RCTs of
statin or any other hypocholesterolemic medication included per-
sons older than 82 years at baseline (4). On the same vein, from
2007 to June 2010, 24 drugs were approved for the treatment of
cancer, and, on average, only 33% of patients included in the reg-
istration trials were aged 65 years or older (6), down from the 36%
reported from 1992 to 2002 (5).
Conducting RCTs with older adults can be challenging for
various reasons including an increased prevalence of multiple
comorbidities and polypharmacy. It is well known that due to
these factors, the line between benefit and harm caused by drug
treatments is really thin in older subjects and not easily evaluable in
routine clinical practice. Indeed, numerous clinical trials excluded
patients with comorbidities such as kidney failure, hypertension,
and diabetes, all of which increase in prevalence with advancing
age. Moreover, even in the absence of specific age- or disease-
based exclusion criteria, older subjects suffering from multiple
comorbidities, with polypharmacy, physical disability, functional
and cognitive impairments, malnutrition, a low familiar and social
care network, or a reduced life expectancy are usually excluded
from RCTs (7). While the exclusion of older subjects from RCTs is
often understandable from the standpoint of completing a study
safely and efficiently, the results of studies that include a very nar-
row, highly selected subset of subjects and exclude most of the
older high-risk patients may be less generalizable to patients cared
outside of the context of clinical trials. This situation may lead to
uncertainty and confusion in clinical decision-making of the older
people.
Beyond clinical decision-making for drug treatment in older
age, prognostic information can be very useful to make a decision
before high-risk interventions such as major surgery (8), partic-
ularly to prevent institutionalization, a second fracture in institu-
tionalized patients, and decrease mortality after a hip fracture (9).
In fact, the decision to proceed with surgery in the frail older adult
requires careful deliberation to determine whether surgical man-
agement is preferable to alternative approaches (8). Older patients
considering surgery should undergo a Comprehensive Geriatric
www.frontiersin.org January 2015 | Volume 1 | Article 61 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pilotto et al. Prognosis and clinical decision-making in older age
Assessment (CGA)-based preoperative assessment, including an
evaluation of comorbidities and functional, cognitive, and nutri-
tional conditions (8). A number of tools are available to facilitate
individualized preoperative risk assessment such as the American
Society of Anesthesiologists (ASA) grade (10) or more comprehen-
sive systems including the Physiological and Operative Severity
Score for the enUmeration of Mortality and morbidity (POS-
SUM) (11) and its modifications (the Portsmouth or P-POSSUM),
the Simplified Acute Physiology Score II (SAPS II) (12), and the
Acute Physiology and Chronic Health Evaluation II (APACHE II)
score (13). However, there are no geriatric-specific tools and no
single instrument incorporates every important geriatric variable
(8). A recent narrative review found that multidomain phenotype
frailty was associated with increased risk for operative mortal-
ity (8). Therefore, for example, the Waterlow score, a tool used
to stratify the risk of pressure sores and a marker of frailty has
been recently compared with the ASA and the P-POSSUM to
predict post-operative mortality and morbidity risk in older sur-
gical patients obtaining good discrimination and accuracy (14).
In the present article, we performed a scoping review of principal
hospital- and community-based prognostic indices in older age,
with a focus on drug treatment.
CLINICAL DECISIONS IN OLDER ADULTS: THE ROLE OF
FRAILTY AND PROGNOSIS
The lack of RCTs in older subjects makes clinical decisions par-
ticularly difficult and not always appropriated, as they are based
mostly on indirect data obtained from adult or younger subjects
with characteristics really dissimilar from the majority of older
subjects. Therefore, there is an urgent need to implement the
scientific evidence in clinical practice permitting to drive more
appropriately clinical decisions in older subjects, especially frail
subjects with higher mortality risk. In fact, the concept of frailty,
as a marker of reduced physiologic reserve, may have direct rele-
vance to clinical care, and clearly identifies a population at greater
risk of adverse health outcomes, including institutionalization,
hospitalization, and death (15).
Recent epidemiological data suggested that frailty is common
among critically ill patients and represents a prognostic determi-
nant of survival and health resource utilization (16). Indeed, frail
individuals are particularly susceptible to adverse drug reactions
(ADRs) (17, 18), and frailty may also result in reduced treat-
ment efficacy (19). For example, treating hypertension in healthy,
robust patients older than 80 years resulted in reduced mortality
and cardiovascular disease end points, but the benefits were not
seen if the older patients were frail (19). The recognition of frail
older subjects therefore may enable improved prognostication and
shared decision-making and identify vulnerable subgroups with
specific needs who might benefit from follow-up and personal-
ized interventions. Indeed, in order to better assess the benefits
and risks of different drug treatments and thus provide an health
care service as close as possible to the real needs of the patients,
avoiding over or underutilization of therapeutic interventions,
recent guidelines recommend including life expectancy in clinical
decision-making paths (20). The ultimate aim is the identification
of subjects who will really benefit from a specific therapeutic inter-
vention avoiding futile diagnostic testing (over-diagnosis) as well
as surgical/invasive procedures, which do not add value and may
cause harm (overtreatment o mistreatment). This action, in addi-
tion,will allow the avoidance of time- and cost-consuming medical
interventions in older subjects not receiving any advantage or in
fact likely displaying a higher risk of ADRs (20).
Clinical prediction rules (CPRs) (also called clinical decision
rules, prediction models, prognostic tools, and risk scores) are
tools designed to assist clinical decision-making. CPRs generally
provide an estimate of the risk of disease, disease outcome, or
the benefit of a diagnostic or therapeutic action. Recently, great
attention has been paid to the proper identification of mortality
prognostic tools that could help clinical decision-making in diag-
nostics and therapeutics to tailor appropriate intervention for the
patient (21). While several risk prediction models have often been
developed and validated in different populations and for differ-
ent outcomes, the prognostic performance of the most popular
and widely used risk models in terms of discrimination, calibra-
tion, generalizability, and reclassification is largely unknown (22).
This is particularly important in advanced age due to the frequent
presence of multiple comorbidities and functional deficits directly
and/or indirectly affecting life expectancy.
MULTIDIMENSIONAL ASSESSMENT AND PROGNOSIS
There is a large and increasing body of evidence indicating that
the prognosis of older patients is strongly related to the presence
of concomitant diseases and to the degree of physical, cognitive,
biological, and social impairment (23). The CGA, capable to effec-
tively exploring these multiple domains of health, is indeed the
multidimensional and multidisciplinary tool of choice to deter-
mine the prognosis of the functionally compromised and frail
older subject (24). Initially, the “first generation” instruments
for the CGA had specific targets, and were applied to specific
older populations with the aim to identify and stratify the risk in
predetermined clinical settings, such as older patients with depres-
sion, cognitive impairment, or physical disability. More recently,
new multidimensional instruments have been introduced, creat-
ing global scores including several items that permitted to explore
several different aspects of different pathologies and reassuming
them in a single, standardized, and simple numerical score, assess-
ing the global impairment of the subject that expressed the risk
of health negative outcomes such as institutionalization, hospi-
talization, or death. Examples of these cumulative CGA-based
indices are the Frailty Index-CGA (FI-CGA) (25) and the Mul-
tidimensional Prognostic Index (MPI) (26, 27) that could be
useful in identifying high-risk older subjects. In particular, the
FI-CGA was a 10-domain multidimensional instrument useful to
assess mild, moderate, and severe frailty (25), while the 8-domain
MPI was developed and validated to predict low, moderate, and
severe risk of all-cause mortality (26, 27). These tools are mainly
based on a list of risk factors that are mentioned to be of great
importance to the concept of frailty (28), including the physical
dimension (nutritional status, physical activity, mobility, strength,
and energy), the psychological dimension (cognition and mood),
and the social dimension (lack of social contacts and social sup-
port). These frailty/prognostic instruments are multidimensional
in nature, and mostly based on a standardized CGA. A recent sys-
tematic review evaluated the clinimetric properties of 20 frailty
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instruments, i.e., the accuracy including discrimination and cal-
ibration, generalizability, feasibility in clinical practice, potential
bias, and the possibility to be used as outcome measures (29).
Unfortunately, the overall results of the assessment by using these
frailty instruments suggested that they are mainly developed and
validated as risk assessment tools, and not as possible outcome
measures and none of these indices has been validated as predictive
tool in clinical decision-making of older people (29).
THE PROGNOSTIC INDICES IN OLDER AGE
HOSPITAL-BASED SETTING
A recent large systematic review identified, from a total num-
ber of over 21,000 titles examined, a small number of prognostic
indices for mortality that meet the requirements of accuracy and
calibration required to be used in a clinical setting involving hospi-
talized older patients (eight indices), living in nursing homes (two
indices), and living in their own homes (six indices) (30). Among
the eight indices selected in the hospital-based setting, only four
tools estimated 1-year mortality on admission: (1) the CARING
index based on four pre-specified predictors (31); (2) the Burden
of Illness Score for Elderly Persons based on functional and lab-
oratory data added to diagnoses from administrative data (32);
(3) the Hospitalized Elder Longitudinal Project (HELP) survival
model (33), a nomogram developed in medicine and intensive
care units patients older than 80 years based on clinical informa-
tion including the APACHE III scale, which requires arterial blood
gas measurement; and (4) the MPI (26, 27). The MPI was the only
one CGA-based predictive tool to be included in this list. None of
the examined indices had accuracy excellent, i.e., a c-statistic value
≥0.9; moreover, for the CARING index, no c-statistic was reported
for the external validation (31), and the Burden of Illness Score for
Elderly Persons model was well calibrated at the extremes, but was
less accurate in middle risk groups (32).
Among these indices used in hospital-based setting, the MPI,
originally developed and validated in two independent cohorts of
older patients hospitalized for acute illnesses or exacerbations of
chronic diseases (26), has been identified as a tool well-calibrated
(<10% of variation between the estimated and the observed mor-
tality rates), with a good discrimination as well as with an accuracy
that is maintained both at 1 month [C-index 0.76, 95% confidence
intervals (CI)= 0.73–0.79] (27) and 1 year (C-index 0.75, 95%
CI= 0.71–0.80) of follow-up (26) (Table 1). Among the totality of
non-disease-specific prognostic indices described in this system-
atic review (30), the MPI was the only tool based on information
obtained from a CGA exploring comprehensively health condi-
tions (multiple comorbidities, medications, risk of pressure sores),
functional (basal and instrumental activities of daily living) cog-
nitive, and nutritional aspects as well as co-habitation status using
standardized rating scales extensively validated and widely used
in the aged population. The multidimensional approach as a key
criterion in defining the clinical outcome in older subjects was
also confirmed by studies showing the higher prognostic mortal-
ity value of MPI compared to the value displayed by the individual
parameters used to build the MPI.
The MPI has been validated in over 12,000 older hospitalized
patients suffering from major diseases leading to death in older
subjects including gastrointestinal bleeding (42), liver cirrhosis
(42), community-acquired pneumonia (37), dementia (38), con-
gestive heart failure (36), chronic kidney disease (39, 40), transient
ischemic attack (41), and cancer (44), showing also a greater pre-
dictive power for all-cause mortality than disease-specific indices
for most of these conditions (36, 37, 42) (Table 1). In addition,
a prospective multicenter study involving over 2,000 hospitalized
older patients recruited in 20 Geriatric Units has shown that MPI
was a significantly more accurate predictor of short- and long-
term all-cause mortality than other three frailty indices commonly
used in clinical practice (34), including the FI-CGA (25) (Table 1).
Also, very recently, in a prospective study of 1,178 older patients
admitted to 20 Geriatrics units, MPI score assessed at hospital
admission was an independent predictor of in-hospital mortal-
ity and the length of hospital stay (45) (Table 1). Finally, the
MPI in older hospitalized patients has been significantly asso-
ciated to other outcomes including re-hospitalization rates and
discharge destination (homes vs. nursing homes) (46), substan-
tially improving the usefulness of this tool for resource planning
purposes.
COMMUNITY-BASED SETTING
Several prognostic instruments that estimated mortality risk from
1 to 5 years have been described and validated in community-
dwelling older populations. Most of these tool are based only on
comorbidity score (47), while other instruments are self-reported
questionnaires that evaluated functional status, age, and gender
(48–50), and also the presence of multiple comorbidities (51). In
community-dwelling cohorts, other indicators, more related to the
pre-disability concept of frailty and to physical performance, have
demonstrated a very powerful prediction of mortality, i.e., gait
speed (52). Very recently, a version of the MPI, based on informa-
tion collected through the Standardized Multidimensional Assess-
ment Schedule for Adults and Aged Persons (SVaMA) has been
developed and validated in two large and independent cohorts
of community-dwelling older subjects (35). This MPI-SVaMA
showed a very good prognostic accuracy to predict 1-month (sur-
vival C-index of 0.83) and 1-year mortality (survival C-index of
0.79) with an excellent calibration. Compared to other prognostic
indices, the MPI-SVaMA differs in some crucial points: (1) the
MPI-SVaMA was the only prognostic tool completely based on
a CGA; (2) all data were collected directly by a multidisciplinary
team, including doctors, a social worker, and a nurse; (3) no par-
ticipant was excluded on the basis of incapacity of self-report; and
(4) the clinical and functional scores used to calculate the prognos-
tic index have been specifically developed and validated in older
subjects. Indeed, although considering the intrinsic limitation of
an indirect comparison among different prognostic instruments,
the MPI-SVaMA demonstrated comparable (47, 49) or higher (48,
50, 51) discrimination as determined by the survival C-index val-
ues (Table 1). Very recently, findings from the Treviso Dementia
(TREDEM) Study demonstrated that the MPI was effective also
in assessing the risk of all-cause mortality and hospitalization in
340 outpatients evaluated in a tertiary care center for cognitive
impairment (43) (Table 1).
Notably, the MPI showed to be an outcome measure sensi-
tive to the antidepressant treatment in late-life major depres-
sive disorder (MDD), suggesting an impact of selective serotonin
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Table 1 | Clinical studies of development and validation of the Multidimensional Prognostic Index (MPI) and predictive values against different
disease-specific prognostic indices.
Disease Patients
number
Accuracy/risk AUC
(95% CI) C-index,
OR, or HR (95% CI)
Follow-up Accuracy of other prognostic indices or
disease-specific prognostic indices vs.
MPI AUC or C-index (95% CI)
Follow-up
Acute diseases or
exacerbations of chronic
diseases (26)
Hospitalized
Development
cohort
838
Validation
cohort
856
0.75 (0.70–0.80)
0.75 (0.71–0.80)
6 months
1 year
Acute diseases or
exacerbations of chronic
diseases (27)
Hospitalized
4,088
0.76 (0.73–0.79) 1 month m-MPI=0.75 (0.72–0.78)
0.72 (0.70–0.74) 1 year m-MPI=0.71 (0.69–0.73)
Acute diseases or
exacerbations of chronic
diseases (34)
Hospitalized
Multicenter
2,033
0.76 (0.72–0.80) 1 month FI-SOF=0.685 (0.64–0.73) p<0.0001
FI-CD=0.738 (0.69–0.78) p<0.0001
FI-CGA=0.724 (0.68–0.77) p<0.0001
0.75 (0.72–0.78) 1 year FI-SOF=0.69, 0.67–0.72, p<0.0001
FI-CD=0.73, 0.70–0.76, p<0.0001
FI-CGA=0.73, 0.70–0.75, p<0.0001
Acute diseases or
exacerbations of chronic
diseases (35)
Community
Development
cohort
7,876
MPI-SVaMA
C-index (95% CI)
0.83 (0.82–0.84)
0.80 (0.78–0.80)
1 month
1 year
C-index
Prognostic score: 0.82
[Lee et al. (49)]
4 years
Combined comorbidity score: 0.79
[Gagne et al. (47)]
1 year
Validation
cohort
4,144
0.83 (0.82–0.85)
0.79 (0.78–0.80)
1 month
1 year
ASSIp prognostic index: 0.75
[Mazzaglia et al. (48)]
15 months
PACE prognostic index: 0.74
[Carey et al. (50)]
2 years
NHIS prognostic score: 0.75
[Schonberg et al. (51)]
5 years
Community-acquired
pneumonia (37)
Hospitalized
134
0.83, 0.75–0.87 1 month PSI=0.71 (0.62–0.78) p=0.019
0.79, 0.71–0.85 6 months PSI=0.69 (0.61–0.77) p=0.035
0.80, 0.72–0.86 1 year PSI=0.75 (0.65–0.82) p=0.185
Transient ischemic attack
(41)
Hospitalized
654
0.82 (0.75–0.89) 1 month
0.80 (0.74–0.86) 6 months
0.77 (0.72–0.82) 1 year
Gastrointestinal bleeding
(42)
Hospitalized
91
0.76 (0.58–0.94) 2 years RRSS=0.57 (0.40–0.74)
GBS=0.61 (0.42–0.80)
Liver cirrhosis (42) Hospitalized
129
0.90 (0.85–0.96) 1 year Child-Pugh score=0.70 (0.52–0.88)
p=0.03
Dementia (38) Hospitalized
262
0.77 (0.73–0.84) 1 month
0.78 (0.72–0.83) 1 year
Dementia (43) Community
340
MPI score: 0–1
OR (95% CI)
6.50 (1.64–25.85)
9.53 (2.90–31.33)
1 year
2.2 years
Risk of hospitalization
Risk of mortality
(Continued)
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Table 1 | Continued
Disease Patients
number
Accuracy/risk AUC
(95% CI) C-index,
OR, or HR (95% CI)
Follow-up Accuracy of other prognostic indices or
disease-specific prognostic indices vs.
MPI AUC or C-index (95% CI)
Follow-up
Congestive heart failure
(36)
Hospitalized
376
Men: 0.83 (0.75–0.90)
Women: 0.80 (0.71–0.89)
1 month NYHA:
Men: 0.63 (0.57–0.69) p=0.015;
Women: 0.65 (0.55–0.75) p=0.064
EFFECT:
Men: 0.69 (0.58–0.79) p=0.045;
Women: 0.71 (0.55–0.87) p=0.443
ADHERE:
Men: 0.65 (0.52–0.78) p=0.023;
Women: 0.67 (0.49–0.83) p=0.171
Chronic kidney disease
(39)
Hospitalized
786
0.70 (0.66–0.73) 1 year eGFR=0.58 (0.54–0.61) p<0.001
Chronic kidney disease
(40)
Hospitalized
1198
C-Index (95% CI)
0.65 (0.62–0.68)
2 years eGFR without MPI=C-index: 0.58
(0.55–0.61) p<0.0001
Adding MPI to eGFR, C-index increased
from 0.58 to 0.65 (p<0.0001)
Inoperable or metastatic
solid cancer (44)
Hospitalized
160
0.91 (0.87–0.96) 6 months
0.87 (0.82–0.93) 1 year
Acute diseases or
exacerbations of chronic
diseases (45)
Hospitalized
1,178
In-hospital mortality:
C-Index 0.85 (0.79–0.91)
HR (95% CI):
MPI-1 Reference
MPI-2 3.48 (1.02–11.88)
MPI-3 8.31 (2.54–27.19)
Length of stay:
Mean (95%CI):
MPI-1 11.29 (0.5) days;
MPI-2 13.73 (1.3) days;
MPI-3 15.30 (1.4) days
AUC, area under the curve; CI, confidence intervals; OR, odds ratio; HR, hazard ratio; m-MPI, MPI-Mini Nutritional Short-Form Examination; FI-SOF, Frailty Index
from the Study of Osteoporotic Fractures; FI-CD, Frailty Index based on the Cumulative Deficit model; FI-CGA, Frailty Index based on a Comprehensive Geriatric
Assessment; MPI-SVaMA, Multidimensional Prognostic Index-Standardized Multidimensional Assessment Schedule for Adults and Aged Persons; ASSIp, Assistenza
Socio-Sanitaria in Italia project; PACE, Program of All-Inclusive Care for the Elderly; NHIS, National Health Interview Survey; PSI, Pneumonia Severity Score; RRSS,
Rockall risk scoring system; GBS, Glasgow–Blatchford bleeding score; NYHA, New York Heart Association Functional Classification; EFFECT, Enhanced Feedback for
Effective Cardiac Treatment; ADHERE, Acute Decompensated Heart Failure National Registry; eGFR, estimated Glomerular Filtration Rate.
reuptake inhibitors also on measures linked to multidimensional
impairment and all-cause mortality, with a clear improvement of
the MPI linked to the antidepressant treatment in older outpa-
tients with late-life MDD (53). Furthermore, in a very recent pilot
study, the integrated treatment of rivastigmine transdermal patch
(RTP) plus cognitive stimulation in Alzheimer’s disease (AD)
patients for 6 months improved significantly cognition, depressive
and neuropsychiatric symptoms, functional status, and mortality
risk assessed with the MPI in comparison with a group of AD
patients receiving only RTP, confirming the possible role of this
multidimensional CGA-based index as an outcome measures also
in dementia (54). Therefore, the MPI score was sensitive to vari-
ations of the subject health over time in outpatients (53, 54) and
hospital-based setting (45), strongly supporting the concept that
considering multidimensional aggregate information could be the
basis of interventions in older age.
PROGNOSIS AND RISK–BENEFIT EVALUATION OF DRUG
TREATMENT IN OLDER AGE
Despite a great number of prognostic indices for mortality has
been developed and validated, there is currently no evidence that
their routine use may improve patient outcomes. Indeed, previ-
ous studies reported that the combined approach including life
expectancies obtained from life tables with clinical and functional
judgments by physicians can facilitate clinical decision-making in
older persons (55, 56). With full access to prognostic information
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derived from accurate and validated predictive tools, physicians
will be better equipped to make clinical decisions that are aligned
with their patients’ needs in terms of safety and efficacy. For exam-
ple, the decision to treat with anticoagulants older frail patients
with atrial fibrillation (AF) is particularly difficult due to the high
risk of serious side effects and low compliance of this treatment.
Indeed, data on subjects with AF have shown that older patients
with different risk of mortality are generally treated differently
from each other (57). A recent retrospective observational study
on almost 1300 community-dwelling frail patients aged 65 years
and older with a previous hospitalization for AF, confirmed that
higher MPI-SVaMA scores were associated with lower rates of
warfarin treatment and higher mortality. However, a significant
association between anticoagulant treatment and increased sur-
vival at 3 years of follow-up was found to be independent from
age and multidimensional impairment. In fact, the analyses for
heterogeneity suggested that the effect of warfarin treatment was
not different among the three MPI-SVaMA groups (58).
Similarly, the clinical decision-making for the administration
of statins to older patients with cardio- and cerebrovascular dis-
ease is under debate (4), with little evidence to support or refute
benefit, particularly in frail older patients with comorbidity and
high mortality risk. Recently, a retrospective observational study
in patients aged 65 years and older with or without statin treat-
ment, demonstrated that higher mortality risk, assessed by the
MPI-SVaMA score, was associated with lower rates of statin pre-
scription. Nonetheless, statin use was significantly associated with
reduced 3-year mortality in all MPI-SVaMA-risk classes, suggest-
ing that increased survival associated with statins in frail older
patients with cardio- and cerebrovascular disease was independent
of age and mortality risk (59).
FUTURE RESEARCH IN THE FIELD
Age distribution of patients should be representative in studies pre-
sented for marketing authorization, and collection of data from all
possible sources might also be required to consolidate knowledge
regarding higher-risk subpopulations. While evidence from RCTs
is used to determine the efficacy of a treatment or intervention
under ideal conditions, studies of observational designs are used to
measure the effectiveness of an intervention in non-experimental,
“real world” scenarios. Indeed, a very recent Cochrane review
assessing the impact of study design on the effect measures esti-
mated suggested that there was little evidence for significant effect
estimate differences between observational studies and RCTs,
regardless of specific observational study design, heterogeneity, or
inclusion of studies of pharmacological interventions (60). There-
fore, preliminary data from observational studies on anticoagulant
and statin treatment suggested that it is time to develop clinical
trials designed specifically for frail older adults (58, 59), until today
not included in RCTs as a result of comorbidity or functional sta-
tus. These trials might be tailored to include novel dosing schemes,
alternative end points such as the impact of therapy on quality of
life, cognitive or physical function, and multidimensional assess-
ment tools to assess functional independence, family support,
and also insurance coverage in older individuals (61). Unfortu-
nately, at present, although non-disease-specific prognostic indices
for older adults hold the promise of improving the targeting of
interventions in advanced age, there is insufficient evidence to
recommend the widespread use of prognostic indices in clinical
practice (30). Large prospective trials that randomize clinicians to
using these tools or not, demonstrating their impact on prognos-
tic estimates, clinical decision-making, and patient outcomes have
not been performed. Future studies are needed to independently
test the accuracy of these prognostic tools in heterogeneous popu-
lations and their ability to improve clinical outcomes before their
widespread use can be recommended. In conclusion, the risk of
mortality may influence the effectiveness of a specific treatment
in older patients. Clinicians need to consider the prognostic infor-
mation obtained through well validated, accurate, and calibrated
predictive tools to identify those patients who may benefit from
drug treatments given with the aim of increasing survival.
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